Sterling Drug

Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader

Retrieved on: 
Tuesday, January 17, 2023
Medical Supplies, Health, Research, Pharmaceutical, Science, Biotechnology, Bristol Myers Squibb, AMAG Pharmaceuticals, API, Avon Products, CTLT, Senior, NYSE, Sterling Drug, Warner–Lambert, Patient, Engineering, Kansas State University, Product strategy, Schering-Plough, Multimedia, Supply chain, Management, Pharmaceutical industry, Catalent, Pfizer, Operation

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America.

Key Points: 
  • Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America.
  • Mr. Zayas will be responsible for all of the company’s North American biologics operations, including its centers of excellence for drug product fill/finish in Bloomington, Indiana, and gene therapy manufacturing in Harmans, Maryland.
  • He will serve on the Executive Leadership Team, reporting directly to Catalent’s President & Chief Executive Officer, Alessandro Maselli.
  • View the full release here: https://www.businesswire.com/news/home/20230117005260/en/
    Ricardo Zayas, who joins Catalent as Senior Vice President, Operations, Biologics North America.

Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

Retrieved on: 
Tuesday, May 24, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, ACI, Company, University, Doctor of Philosophy, Pharmacology, NASH, Annual report, Postherpetic neuralgia, Nasdaq, IND, Form 10-K, Solution, Obesity, Restless legs syndrome, CB1, Pharmacy, Research, United Kingdom, FDA, CHDR, Securities Act of 1933, Securities Exchange Act of 1934, Speech disorder, Kodak, Medication, Technology, Drug Quality and Security Act, Berkeley, Drug development, Therapy, Degenerative disease, HIV, SEC, Drug discovery, Lists of diseases, Sterling Drug, Gilead Sciences, Pharmaceutical industry, Biochemistry

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the Company or Anebulo), today announced the appointment of Dr. Kenneth Cundy, Ph.D. as Chief Scientific Officer of the Company.

Key Points: 
  • Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the Company or Anebulo), today announced the appointment of Dr. Kenneth Cundy, Ph.D. as Chief Scientific Officer of the Company.
  • Before CohBar, Dr. Cundy was Chief Scientific Officer at XenoPort, Inc., a biopharmaceutical company focused on therapeutics for neurological disorders.
  • Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder.
  • Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

BioTheryX Appoints Nancy Miller-Rich as Chair of Its Board of Directors

Retrieved on: 
Wednesday, February 23, 2022
Schering-Plough, Board, Novartis, Group, Adena Miller Rich, Therapy, Chairperson, Social media, Forecasting, Protein, Senior, Sterling Drug, LinkedIn, Multimedia, Leadership, Independent Board for Presbyterian Foreign Missions, Cancer, SAN, Intercept Pharmaceuticals, Patient, Merck & Co., Merck, Health, Management

SAN DIEGO, Feb. 23, 2022 /PRNewswire/ --BioTheryX, Inc., a clinical-stage company focused on developing targeted protein degraders to create life-saving medicines, today announced that Nancy Miller-Rich has assumed the role of Chair of the BioTheryX Board of Directors.

Key Points: 
  • SAN DIEGO, Feb. 23, 2022 /PRNewswire/ --BioTheryX, Inc., a clinical-stage company focused on developing targeted protein degraders to create life-saving medicines, today announced that Nancy Miller-Rich has assumed the role of Chair of the BioTheryX Board of Directors.
  • "Nancy has honed her commercial and business strategy expertise over 35 years in the biopharmaceutical industry.
  • Her vision and passion as Chair of the Board will be invaluable as we continue to build BioTheryX into a leader in next generation protein degradation," said Philippe Drouet, President and Chief Executive Officer of BioTheryX.
  • "I am honored to assume the role of Chair of the Board at such a pivotal time for BioTheryX.

Azurity Pharmaceuticals Announces Richard Blackburn as New CEO

Retrieved on: 
Friday, February 18, 2022
United States v. Parke, Davis & Co., Patient, Inflammation, Endocrinology, CEO, Azure Power, Blackburn, Sanofi, Neurology, Sterling Drug, Immunology, Board, Marketing, Multimedia, Industry, Pharmaceutical industry, Pfizer

Amit Patel, who has been serving as CEO since early 2020, will remain in his role as Executive Chairman.

Key Points: 
  • Amit Patel, who has been serving as CEO since early 2020, will remain in his role as Executive Chairman.
  • Blackburn joins Azurity after more than 20 years at Pfizer, where he most recently served as Global President, Inflammation & Immunology.
  • "I'm delighted to join Azurity as CEO and it is a privilege to be part of this dynamic and growing company," Blackburn said.
  • Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company that focuses on innovative products that meet the specific needs of underserved patient segments.

OcyonBio Appoints Ricardo Zayas as Chief Operating Officer

Retrieved on: 
Monday, February 14, 2022
Avon Products, Product strategy, CEO, API, CMC, COO, IP, GLOBE, Sterling Drug, Schering-Plough, CGMP, FDA, Kansas State University, AMAG Pharmaceuticals, Acquisition, CDMO, Warner–Lambert, DNA, Supply chain, Industry, LLC, Pharmaceutical industry, Bristol Myers Squibb, Pfizer

AGUADILLA, Puerto Rico, Feb. 14, 2022 (GLOBE NEWSWIRE) -- OcyonBio, LLC announces it has appointed Ricardo Zayas its Chief Operating Officer.

Key Points: 
  • AGUADILLA, Puerto Rico, Feb. 14, 2022 (GLOBE NEWSWIRE) -- OcyonBio, LLC announces it has appointed Ricardo Zayas its Chief Operating Officer.
  • Ricardo Zayas was most recently Executive Vice President and Head of Operations for Romark Global Pharma, LLC.
  • I am proud to help develop this expertise in Puerto Rico," stated Ricardo Zayas, COO.
  • OcyonBio provides a company with its own space, so there is no need to build an expensive facility.

Scipher Medicine Appoints Richard Blackburn to its Advisory Board

Retrieved on: 
Thursday, December 16, 2021
Biotechnology, Pharmaceutical, Health, Medical Devices, Sterling Drug, LinkedIn, Solution, Immunology, Physician, Sickle Cell Anemia, a Molecular Disease, Degenerative disease, Medicine, Time, Inflammation, Patient, Therapy, Parke-Davis, Janssen Pharmaceuticals, Multimedia, Twitter, Precision medicine, Pharmaceutical industry, Management, Pfizer, Facebook

Scipher Medicine , a precision immunology company matching each patient with their most effective therapy, today announced the appointment of Richard Blackburn to its advisory board.

Key Points: 
  • Scipher Medicine , a precision immunology company matching each patient with their most effective therapy, today announced the appointment of Richard Blackburn to its advisory board.
  • View the full release here: https://www.businesswire.com/news/home/20211216006082/en/
    Richard Blackburn joins Scipher Medicine advisory board.
  • Scipher Medicine is bringing forward innovative precision medicine solutions that benefit patients, physicians, and the healthcare system.
  • We are pleased to welcome Richard to the team, said Alif Saleh, chief executive officer of Scipher Medicine.

BioTheryX Announces Appointments of Three New Members to its Board of Directors

Retrieved on: 
Friday, August 6, 2021
Industry, Sterling Drug, GlaxoSmithKline, Company, Immunology, University of Medicine and Dentistry of New Jersey, Certified Public Accountant, Sarbanes–Oxley Act, CEO, Intercept Pharmaceuticals, Novartis, Board, University, MD, Board of directors, Therapy, Public policy, Patient, Ithaca College, Biogen, Merck & Co., Business administration, Bioverativ, Development, Colby College, Group, Merck, Drug development, Internal medicine, Oncology, Cancer, Multimedia, Leadership, Schering-Plough, Dentistry, Motu Economic and Public Policy Research, LinkedIn, SEC, PricewaterhouseCoopers, Robert Wood Johnson Medical School, Controller, Accounting, SAN, Risk management, Senior, Pharmaceutical industry, Management

"Nancy is a veteran life sciences executive and board member with significant expertise in corporate and commercial strategy.

Key Points: 
  • "Nancy is a veteran life sciences executive and board member with significant expertise in corporate and commercial strategy.
  • We look forward to Nancy, John, and Diantha's guidance as we aim to build a leading protein degradation company."
  • Nancy Miller-Rich has 35 years of experience in the healthcare industry, with significant expertise in business development and commercial strategy.
  • John A. Hohneker, M.D.brings over 30 years of drug development and leadership experience within the biotech and pharmaceutical industry to the BioTheryX board.